Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Down 65.6% in June

Cel-Sci Corporation (NYSEAMERICAN:CVM) saw a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 263,542 shares, a drop of 65.6% from the June 15th total of 765,484 shares. Currently, 1.7% of the company’s shares are short sold. Based on an average daily volume of 424,964 shares, the days-to-cover ratio is currently 0.6 days.

Hedge Funds Weigh In On Cel-Sci

A number of institutional investors have recently bought and sold shares of CVM. Vanguard Group Inc. boosted its position in Cel-Sci by 59.7% during the 3rd quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock valued at $2,692,000 after acquiring an additional 109,352 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Cel-Sci by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock valued at $417,000 after purchasing an additional 18,432 shares in the last quarter. Bank of America Corp DE grew its stake in Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock worth $94,000 after purchasing an additional 39,190 shares during the period. Renaissance Technologies LLC lifted its position in Cel-Sci by 133.0% during the first quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock valued at $115,000 after buying an additional 20,484 shares during the period. Finally, State Street Corp boosted its holdings in shares of Cel-Sci by 9.9% during the 4th quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after buying an additional 2,300 shares in the last quarter. 12.08% of the stock is owned by institutional investors.

Cel-Sci Trading Down 5.7%

CVM traded down $0.07 during midday trading on Tuesday, reaching $1.15. 321,732 shares of the company’s stock traded hands, compared to its average volume of 381,109. Cel-Sci has a 52 week low of $0.89 and a 52 week high of $13.48. The company has a debt-to-equity ratio of 0.64, a current ratio of 0.60 and a quick ratio of 0.54. The firm has a fifty day moving average of $1.29 and a two-hundred day moving average of $3.34. The stock has a market capitalization of $20.10 million, a price-to-earnings ratio of -0.12 and a beta of 0.64.

Cel-Sci (NYSEAMERICAN:CVM) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.67) earnings per share for the quarter.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.